We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals
JAZZ

471 hedge funds and large institutions have $8.31B invested in Jazz Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 168 increasing their positions, 154 reducing their positions, and 64 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more call options, than puts

Call options by funds: $14.8M | Put options by funds: $8.22M

1.2% more ownership

Funds ownership: 89.26% → 90.46% (+1.2%)

9% more repeat investments, than reductions

Existing positions increased: 168 | Existing positions reduced: 154

9% less first-time investments, than exits

New positions opened: 58 | Existing positions closed: 64

3% less funds holding

Funds holding: 486 → 471 (-15)

6% less capital invested

Capital invested by funds: $8.82B → $8.31B (-$513M)

38% less funds holding in top 10

Funds holding in top 10: 8 → 5 (-3)

Holders
471
Holders Change
-15
Holders Change %
-3.09%
% of All Funds
7.51%
Holding in Top 10
5
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-37.5%
% of All Funds
0.08%
New
58
Increased
168
Reduced
154
Closed
64
Calls
$14.8M
Puts
$8.22M
Net Calls
+$6.55M
Net Calls Change
+$36.6M

Top Buyers

1
Swedbank
Swedbank
Sweden
+$114M
2
Millennium Management
Millennium Management
New York
+$106M
3
BG
Baupost Group
Massachusetts
+$70.8M
4
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$68.5M
5
DTC
Deep Track Capital
Connecticut
+$48.3M

Top Sellers

1
JP Morgan Chase
JP Morgan Chase
New York
-$107M
2
Victory Capital Management
Victory Capital Management
Texas
-$61.3M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$61.2M
4
Citadel Advisors
Citadel Advisors
Florida
-$52.6M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$29.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
426
Schubert & Co
Texas
$2.78K -$1.18K -8 -30%
TWC
427
TD Waterhouse Canada
Ontario, Canada
$2.62K +$592 +4 +29%
JWM
428
Janiczek Wealth Management
Colorado
$2.04K – – –
BWA
429
BDO Wealth Advisors
Florida
$1.76K -$2.52K -17 -59%
BC
430
Barrett & Company
Rhode Island
$1.76K -$444 -3 -20%
BBPWM
431
Blue Bell Private Wealth Management
Pennsylvania
$1.76K – – –
CA
432
Clearstead Advisors
Ohio
$1.76K – – –
MAWCM
433
Mine & Arao Wealth Creation & Management
California
$1.76K – – –
OLVIG
434
Oliver Lagore Vanvalin Investment Group
Michigan
$1.76K – – –
FSWA
435
Financial Synergies Wealth Advisors
Texas
$1.46K – – –
BAAM
436
Baker Avenue Asset Management
California
$1.46K -$1.77K -12 -55%
PFG
437
Piershale Financial Group
Illinois
$1.46K – – –
RTL
438
Red Tortoise LLC
Georgia
$1.46K +$1.48K +10 New
Commonwealth Equity Services
439
Commonwealth Equity Services
Massachusetts
$1.33K -$44.4K -300 -3%
RA
440
Rise Advisors
New York
$1.32K – – –
AAS
441
Ameritas Advisory Services
Nebraska
$1.3K +$1.33K +9 New
AF
442
Advisornet Financial
Minnesota
$1.17K -$592 -4 -33%
DI
443
Disciplined Investments
Oklahoma
$1.17K -$444 -3 -27%
CWM
444
CarsonAllaria Wealth Management
Illinois
$1.17K – – –
HWA
445
Heritage Wealth Advisors
Virginia
$1.17K – – –
CTA
446
Colonial Trust Advisors
South Carolina
$1.17K +$1.18K +8 New
BCMLT
447
Beacon Capital Management LLC (Tennessee)
Tennessee
$1.17K -$1.03K -7 -47%
FGAM
448
Financial Gravity Asset Management
Texas
$1.13K -$1.92K -13 -8%
GI
449
Gradient Investments
Minnesota
$1.02K – – –
FMP
450
Financial Management Professionals
Texas
$1K – – –
16 17
18
19 20

JAZZ Hedge Fund Activity: Q1 2023 in Review

471 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2023, worth a combined $8.31B — down 5.8% from $8.82B a quarter earlier.

Sellers outnumbered buyers: 64 funds closed out of JAZZ and 58 opened new positions — a net loss of 6 holders — while 154 trimmed existing stakes and 168 added.

The largest buyer was Swedbank, adding an estimated $114M. The largest seller was JP Morgan Chase, cutting an estimated $107M.

  • 471 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2023, down from 486 in Q4 2022.
  • Funds reported $8.31B of Jazz Pharmaceuticals stock for Q1 2023, down 5.8% quarter-over-quarter.
  • 58 funds opened new Jazz Pharmaceuticals positions in Q1 2023 and 64 closed out, a net change of -6 holders.
  • The largest Jazz Pharmaceuticals buyer in Q1 2023 was Swedbank, an estimated $114M added.
  • The largest Jazz Pharmaceuticals seller in Q1 2023 was JP Morgan Chase, an estimated $107M sold.

Based on aggregated 13F filings for Q1 2023.